Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and Drug Administration approval last month.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity. It suppresses appetite and reduces caloric intake, making it particularly effective for individuals whose OSA symptoms are exacerbated by excess weight.
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%.
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
Zepbound Approved for Obstructive Sleep Apnea in Patients With Obesity
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound,
You can't cure sleep apnea but you can manage it — doctors explain how
Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...
Impacts8h
What a Home Sleep Study Reveals
Sleep apnea affects millions of people worldwide and prevents them from getting quality sleep. It negatively affects patients ...
Rolling Out3d
How a sleep mask for apnea reduces high blood pressure risk
Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...
I Started Waking Up Hours Before My Alarm, So I Asked a Sleep Doctor What to Do
When I have sleep problems, it's usually not about struggling to fall asleep; I conk out pretty quickly once I get in bed.
The best sleep tech from CES 2025 so far — from brain bands to singing smart rings
From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...
Optical imaging technique offers more precise diagnosis of sleep apnea
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...
Future Market Insights5d
Sleep Apnea Diagnostic Systems Industry to Nearly Double, Reaching USD 9.27 Billion by 2033 at a 6.8% of CAGR
The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...